InDex Pharmaceuticals Holding (OM:INDEX) - Prezzo delle azioni, notizie e analisi

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

INDEX Panoramica delle azioni

Engages in the research and development of pharmaceuticals for immunological diseases.

INDEX analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Earnings have grown 2.7% per year over the past 5 years

Analisi del rischio

Earnings are forecast to decline by an average of 48.5% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (SEK287M)

InDex Pharmaceuticals Holding AB (publ) Concorrenti

ODI Pharma

NGM:ODI

SEK 49.3m

Ziccum

OM:ZICC

SEK 38.3m

Corline Biomedical

OM:CLBIO

SEK 182.7m

AcuCort

NGM:ACUC

SEK 109.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per InDex Pharmaceuticals Holding
Prezzi storici delle azioni
Prezzo attuale dell'azione	SEK 0.55
Massimo di 52 settimane	SEK 0.93
Minimo di 52 settimane	SEK 0.20
Beta	-0.21
1Variazione di 1 mese	35.15%
Variazione a 3 mesi	88.28%
Variazione di 1 anno	-4.55%
3Variazione a 3 anni	-63.84%
Variazione a 5 anni	-93.87%
Variazione dall'IPO	-92.20%

Notizie e aggiornamenti recenti

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Jul 11

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Jan 21

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Aug 31

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

Mar 29

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

Feb 04

How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

Dec 21

Rendimenti per gli azionisti

	INDEX	SE Pharmaceuticals	SE Mercato
7D	1.1%	-2.4%	0.05%
1Y	-4.5%	46.6%	28.1%

Ritorno vs Industria: INDEX underperformed the Swedish Pharmaceuticals industry which returned 88.4% over the past year.

Rendimento vs Mercato: INDEX underperformed the Swedish Market which returned 14.1% over the past year.

Volatilità dei prezzi

Is INDEX's price volatile compared to industry and market?
INDEX volatility
INDEX Average Weekly Movement	7.5%
Pharmaceuticals Industry Average Movement	10.7%
Market Average Movement	5.4%
10% most volatile stocks in SE Market	11.1%
10% least volatile stocks in SE Market	3.3%

Prezzo delle azioni stabile: INDEX's share price has been volatile over the past 3 months.

Volatilità nel tempo: INDEX's weekly volatility (7%) has been stable over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2000	4	Jenny Sundqvist	www.indexpharma.com

InDex Pharmaceuticals Holding AB (publ) Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di InDex Pharmaceuticals Holding con la sua capitalizzazione di mercato?
INDEX statistiche fondamentali
Capitalizzazione di mercato	SEK 286.59m
Guadagni(TTM)	-SEK 56.48m
Ricavi(TTM)	SEK 108.34m

2.7x

Rapporto P/S

-5.1x

Rapporto P/E

INDEX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
INDEX Conto economico (TTM)
Ricavi	SEK 108.34m
Costo del fatturato	SEK 4.03m
Profitto lordo	SEK 104.31m
Altre spese	SEK 160.79m
Guadagni	-SEK 56.48m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

Aug 20, 2024

Utile per azione (EPS)	-0.11
Margine lordo	96.28%
Margine di profitto netto	-52.13%
Rapporto debito/patrimonio netto	0%

Come si è comportato INDEX nel lungo periodo?

Vedi performance storica e confronto

This company is no longer active

INDEX Panoramica delle azioni

Premi

Analisi del rischio

InDex Pharmaceuticals Holding AB (publ) Concorrenti

NGM:ODI

SEK 49.3m

OM:ZICC

SEK 38.3m

OM:CLBIO

SEK 182.7m

NGM:ACUC

SEK 109.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction.

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction.

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

InDex Pharmaceuticals Holding AB (publ) Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024

InDex Pharmaceuticals Holding AB (publ) Discontinues the Development of Cobitolimod

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

InDex Pharmaceuticals Holding AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

Third quarter 2023 earnings released: kr0.07 loss per share (vs kr0.006 loss in 3Q 2022)

New major risk - Share price stability

InDex Pharmaceuticals Holding AB (publ) Discontinues Cobitolimod Phase III Program

InDex Pharmaceuticals Holding AB (publ) Announces Composition of the Nomination Committee

InDex Pharmaceuticals Holding AB (Publ) Receives New Patent for Cobitolimod in South Korea

InDex Pharmaceuticals Holding AB (publ) Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude

InDex Pharmaceuticals Holding AB (publ) Announces Positive Results from the Pharmacokinetic (PK) Study

InDex Pharmaceuticals Holding AB (publ) Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Deputy CEO & Chief Financial Officer recently bought kr66k worth of stock

Price target decreased by 31% to kr1.90

InDex Pharmaceuticals Holding AB (publ) Updates the Timeline of the Phase III Study CONCLUDE with cobitolimod

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Final Results on Apr 12, 2023

InDex Pharmaceuticals Holding AB (publ) to Report Q1, 2023 Results on May 24, 2023

Third quarter 2022 earnings released: kr0.006 loss per share (vs kr0.05 loss in 3Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

InDex Pharmaceuticals Holding AB (publ) Appoints Jenny Sundqvist as New CEO, Effective January 1, 2023

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: kr0.04 loss per share (vs kr0.08 loss in 2Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Successful Interactions with the Pmda for the Clinical Development of Cobitolimod in Japan

InDex Pharmaceuticals Holding AB (publ) Announces Board Appointments

First quarter 2022 earnings released: kr0.04 loss per share (vs kr0.02 loss in 1Q 2021)

InDex Pharmaceuticals Strengthens the Organization with Eva Arlander as Chief Development Officer and Announces Changes in the Composition of the Management Team

Full year 2021 earnings released: kr0.21 loss per share (vs kr0.24 loss in FY 2020)

InDex Pharmaceuticals Holding AB (publ) Announces CEO Changes

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

Full year 2021 earnings: EPS misses analyst expectations

InDex Pharmaceuticals Holding AB (publ) Announces Resignation of Pernilla Sandwall as Chief Operating Officer

InDex Pharmaceuticals Enrols First Patient in the Pk Study with Cobitolimod

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

InDex Pharmaceuticals Holding AB (publ) Enrolls First Patient in Phase III Study CONCLUDE with Cobitolimod in Ulcerative Colitis

Second quarter 2021 earnings released

InDex Pharmaceuticals Receives FDA Clearance to start the Phase III Study CONCLUDE with Cobitolimod

InDex Pharmaceuticals Holding AB (publ) to Conduct Clinical Pharmacokinetic Study (PK Study) with Cobitolimod in Sweden

InDex Pharmaceuticals Receives First Regulatory Approval to Start the Phase III study CONCLUDE with Cobitolimod

Independent Director Stig Pedersen has left the company

Independent Director Yilmaz Mahshid has left the company

InDex Pharmaceuticals Holding AB (publ) Announces Patient Recruitment for Phase III Study CONCLUDE is Planned to Initiate after Summer

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

InDex Pharmaceuticals Holding AB (Publ) Announces Changes in the Nomination Committee for the 2021 Annual General Meeting

Revenue in line with expectations

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 23, 2021

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

New 90-day low: kr3.88